Research

CLINICAL TRIALS

Bone Marrow Transplant

TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

This phase I trial studies the safety of transplantation with a haploidentical donor (typically Mother or Father) peripheral blood stem cell graft depleted of TCRαβ+ cells (which cause GVHD) and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period. Zoledronate expands gamma delta T cells, which have anti-tumor properties, speed up immune recovery but do not mediate GVHD.

For more information or questions, please contact us via email at PedsHemOncResearch@lists.wisc.edu or call us at 608-890-8070

Eligible Cancers

Trial treatment diagram

  • Leukemia:  Acute Myeloid  & Acute Lymphoblastic
  • Lymphoma:  Hodgkin & Non-Hodgkin
  • Myelodysplastic Syndrome
  • Myeloproliferative Syndrome
  • Sarcomas:  Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma
  • Primitive Neuroectodermal Tumor
  • Neuroblastoma

Ages eligible for study: 7 months to 21 years

Hematologic Malignancies

For more information or questions, please contact us via email at PedsHemOncResearch@lists.wisc.edu or call us at 608-890-8070

Eligible Leukemia and Lymphomas

Leukemia Clinical Trials

Lymphoma Clinical Trials

Solid Tumors

For more information or questions, please contact us via email at PedsHemOncResearch@lists.wisc.edu or call us at 608-890-8070

Eligible Solid Tumors

Sarcomas Other Tumors Other Oncologic Diseases
Ewing Sarcoma
Osteosarcoma
Rhabdomyosarcoma
Neuroblastoma
Wilms Tumor
Hepatoblastoma
Retinoblastoma
Germ Cell Tumors
Endocrine Tumors, including Adrenocortical carcinoma
Thyroid Tumors
Langerhans’ Cell Histiocytosis (LCH)
Hemophagocytic Lymphohistiocytosis (HLH)
Vascular malformations (Hemangiomas and lymphangiomas)
Neurofibromatosis (Malignant Peripheral Nerve Sheath Tumor)

Neuroblastoma Clinical Trials

Sarcoma Clinical Trials

Wilms Tumor Clinical Trials

Late Effects

The Caring for Life Clinic is designed specifically to help the survivors of childhood cancer.

For more information or questions, please contact us via email at PedsHemOncResearch@lists.wisc.edu or call us at 608-890-8070

Clinic Goals

  • Detect and treat problems related to being a childhood cancer survivor
  • Share ongoing research findings with childhood cancer survivors
  • Provide health maintenance education about potential risks and preventive behaviors
  • Provide information to school personnel and employers to meet the special needs of survivors
  • Provide emotional support to both survivors and family members
  • Empower survivors of cancer to advocate for their rights
  • Facilitate transition of medical care to an adult care system

Late Effects Clinical Trials

Neuro-oncology

For more information or questions, please contact us via email at PedsHemOncResearch@lists.wisc.edu or call us at 608-890-8070

Eligible Brain & Spinal Tumors

Brain & Spinal Tumor Clinical Trials

Recent Publications

Kenneth DeSantes – view all publications

Christian Capitini – view all publications

Carol Diamond – view all publications

Inga Hofmann – view all publications

Margo Hoover-Regan – view all publications

Mario Otto – view all publications

Diane Puccetti – view all publications

Paul Sondel – view all publications

Current Research Support

Christian Capitini, MD

Mario Otto, MD, PhD

Paul Sondel, MD, PhD

Midwest Athletes Against Childhood Cancer, “Prognostic markers and therapeutic targets in GATA2-related myelodysplastic syndromes and leukemia” (2017-2019). Hofmann, PI

EvansMDS, “Prognostic markers and therapeutic targets in GATA2-related myelodysplastic syndromes” (2017-2019). Hofmann, PI

Midwest Athletes Against Childhood Cancer, “Support for research data management” (2007-2019). DeSantes, PI

Midwest Athletes Against Childhood Cancer, “Treatment of relapsed or refractory neuroblastoma with ex-vivo activated and expanded haploidentical NK cells and continuous infusion Hu14.18-IL2” (2017-2019). DeSantes, PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6902: A retrospective and cross-sectional analysis of patients treated for SCID” (2017-ongoing), DeSantes, site PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6903: Analysis of patients treated for chronic granulomatous disease” (2016-ongoing), DeSantes, site PI

Children’s Hospital Los Angeles & NIH/NIAID (U54 AI082973), “PIDTC #6901: A prospective natural history study of diagnosis, treatment and outcomes of children with SCID disorders” (2016-ongoing), DeSantes, site PI

Children’s Hospital of Philadelphia & Seattle Genetics, Inc., “A randomized phase III study of brentuximab vedotin for newly diagnosed classical hodgkin lymphoma in children and adolescents (AHOD1331)” (2016-ongoing). DeSantes, site PI

Mesoblast, “A single-arm, prospective study of remestemcel-L, ex-vivo cultured adult human mesenchymal stromal cells, for the treatment of pediatric patients who have failed to respond to steroid treatment for acute GVHD” (2016-ongoing). DeSantes, PI

Macrogenics, “UW16107: A phase 1, open-label, dose escalation study of MGA271 in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors” (2016-ongoing). DeSantes, PI

Boehringer Ingelheim, Ltd., “Phase I open label, dose escalation trial to determine the MTD, safety, PK and efficacy of afatinib monotherapy in children aged 2 years to <18 years with recurrent/refractory neuroectodermal tumours, rhabdomyosarcoma and/or other solid tumours” (2016-ongoing). DeSantes, PI

Nationwide Children’s Hospital, “The “head start 4” protocol newly diagnosed children (less than 10 years old) with medulloblastoma and other central, nervous system embryonal tumors, phase IV” (2015-ongoing). DeSantes, site PI

Children’s Hospital of Philadelphia & Children’s Oncology Group, “Everychild protocol: a registry, eligibility screening, biology and outcome study (APEC14B1)” (2015-ongoing). DeSantes, PI

Children’s Hospital of Philadelphia & Hoffmann-LaRoche, Inc., “Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients (ANHL1131)” (2014-ongoing). DeSantes, PI

Children’s Hospital of Philadelphia, “AALL1131 – A phase III randomized trial for newly diagnosed high risk B-precursor acute lymphoblastic leukemia testing clofarabine in the very high risk stratum (AALL1131)” (2014-ongoing). DeSantes, PI

Solving Kids Cancer, “Phase I trial of ex-vivo expanded haploidentical NK cells and Hu14.18-IL2 for children with relapsed/refractory neuroblastoma” (2012-2017). DeSantes, PI

Children’s Hospital of Philadelphia & Bristol-Myers Squibb Company, “A phase 2 multi-center, historically-controlled study of dasatinib added to standard chemotherapy in pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia” (2012-ongoing). DeSantes, site PI

Children’s Hospital of Philadelphia & Millenium Pharmaceuticals, “A phase III randomized trial for patients with de novo AML using bortezomib and sorafenib for patients with high allelic ratio FLT2/ITD (AAML1031)” (2012-ongoing). DeSantes, site PI